Literature DB >> 6893952

Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.

R P Warrell, D J Straus, C W Young.   

Abstract

A disease-oriented trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide) given once every 3 weeks was undertaken in patients with advanced non-Hodgkin's lymphoma. None of 15 adequately treated patients achieved complete or partial remissions. Toxicity was mild-to-moderate, consisting of myelosuppression (principally granulocytopenia) and malaise. The lack of any major responses in this number of patients suggests that, in this schedule, the drug is not useful in therapy for advanced non-Hodgkin's lymphoma.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6893952

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  3 in total

1.  The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit.

Authors:  J W Paxton; S E Foote; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.

Authors:  J W Paxton; P C Evans; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.

Authors:  J W Paxton; J L Jurlina
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.